Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2023-10-01
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Transcranial Direct Stimulation on Cognitive Functions of Healthy Adults
NCT04873804
Interference With Cognitive Control by Transcranial Direct Current Stimulation
NCT01903538
tDCS in the Management of Post-COVID Disorders
NCT06074848
Modulation of Cognitive Control by Transcranial Direct Current Stimulation
NCT01652391
Effects of tDCS-enhanced Cognitive Control Training on Depression
NCT03518749
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The dorsolateral prefrontal cortex (DLPFC) is the central region associated with executive functions, and damage to this region is associated with difficulty in regulating behavioral responses, memory-retrieval, and inability to demonstrate appropriate motor behavior. Damages in this region are associated with cognitive loss in related areas (Liu et al., 2021; Brak et al., 2022). tDCS, on the other hand, stands out as a promising method for patients with Covid-19 infection and subjective cognitive complaints, and appears to act by modulating functional connectivity (Baptista, 2020; Linnhoff, 2023; Yulug B). Increased connectivity between the hippocampus and other DMN nodes such as the dorsal attention network, control, attention-attractiveness network, and sensori-motor networks was detected in fMRI with atDCS stimulation (Manenti et al., 2020; Meinzer et al., 2015). In this context, improvement in neurocognitive tests and changes in functional imaging can be detected with stimulation of the relevant regions of the cortex with tDCS in patients who have had Covid-19 infection and have subjective cognitive complaints. In patients with Covid-19 infection, stimulation of the relevant regions with tDCS resulted in improvement in cognitive functions such as working memory and cognitive control. (Baptista, 2020; Linnhoff, 2023; Yulug B,2023). At this point, DLPFC stimulation may also result in improved cognitive functions regarding encoding and recall.
From this point of view, in this study -based on the studies referenced in the text-, bilateral stimulation of the DLPFC region with anodal tDCS (atDCS) increased performance in neurocognitive abilities, especially memory and executive functions, in patients who had Covid-19 infection and had subjective cognitive complaints. The methodical mesh is shaped in the context of this template, hypothesizing that it will result in In addition, in the fMRI studies mentioned above, it is aimed to point out that tDCS stimulation increases the coherence between DMN networks and to examine the effect of tDCS stimulation on DMN network connectivity and connectivity with the hippocampal region with reference to the role of PMN in patients with Covid-19 infection and subjective cognitive complaints. From this point of view, the aim of this study is dorsolateral prefrontal cortex (DLPFC) active tDCS (transcranial direct stimulation/transcribed) in patients with covid-19 infection and subjective cognitive complaints.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interventional
Active tDCS stimulation will be applied over the scalp for 20 minutes at an intensity of 2 mA. Stimulation will be given for 5 days. The application will be made to the patient who has had 30 Covid and has cognition complaints in a randomized manner.
Transcranial Direct Stimulation
2 mA, 20 min, 5 days
Sham
For the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.
Transcranial Direct Stimulation
2 mA, 20 min, 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Direct Stimulation
2 mA, 20 min, 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being between the ages of 18-50
* 21 days have passed since the disease onset date
Exclusion Criteria
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alanya Alaaddin Keykubat University
OTHER
Istanbul Medipol University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Lutfu Hanoglu, MD
Prof. Dr. MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Burak Yuluğ, Prof. DR. MD
Role: STUDY_DIRECTOR
Alanya Alaaddin Keykubat Üniversitesi
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alanya Alaaddin Keykubat Üniversitesi
Antalya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023IMU_ALKU_COVID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.